title: Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
abstract: This report updates the combined experience of four centres involved in the long-term treatment of transfusional iron overload in 84 patients with the oral iron chelator deferiprone (L1) over 167 patient-years. The source of L1 was variable, including two university research laboratories and three pharmaceutical firms. Compliance was rated as excellent in 48%, intermediate in 36%, and poor in 16% of patients. On a mean L1 dose of 73-81 mg/kg/d, urinary iron excretion was stable, at around 0.5 mg/kg/d, with no indication of a diminishing response with time. Serum ferritin showed a very steady decrease with time from an initial mean +/- 1 SD of 4207 +/- 3118 to 1779 +/- 1154 micrograms/l after 48 months (P < 0.001). 17 patients abandoned L1 therapy. Major complications of L1 requiring permanent discontinuation of treatment included agranulocytosis (three), severe nausea (four), arthritis (two) and persistent liver dysfunction (one). The remaining patients abandoned treatment because of low compliance (three) and conditions unrelated to L1 toxicity (four). Lesser complications permitting continued L1 treatment included transient mild neutropenia (four), zinc deficiency (12), transient increase in liver enzymes (37), moderate nausea (three) and arthropathy (17). There was no treatment-related mortality. Although the complications associated with L1 treatment are significant and require close monitoring, they do not preclude effective long-term therapy in the vast majority of patients. Further well-controlled prospective studies of L1 are required in order to enable proper judgement of its suitability for general long-term clinical use.
authors.affiliation: Department of Haematology, Royal Free Hospital, London, U.K.
authors.forename: F N
authors.initials: FN
authors.lastname: al-Refaie
authors.forename: C
authors.initials: C
authors.lastname: Hershko
authors.forename: A V
authors.initials: AV
authors.lastname: Hoffbrand
authors.forename: M
authors.initials: M
authors.lastname: Kosaryan
authors.forename: N F
authors.initials: NF
authors.lastname: Olivieri
authors.forename: P
authors.initials: P
authors.lastname: Tondury
authors.forename: B
authors.initials: B
authors.lastname: Wonke
mesh_terms: D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D001168:Arthritis / Q000139:chemically induced; D056486:Chemical and Drug Induced Liver Injury; D000077543:Deferiprone; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006486:Hemosiderosis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000652:urine; D007502:Iron Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron